IMUNON (IMNN) announced that an abstract highlighting new, highly encouraging, Overall Survival data from the Phase 2 OVATION 2 Study of ...

Highly promising survival data from OVATION 2 Study of treatment of newly diagnosed advanced ovarian cancer to be presented Initiation of Phase 3 trial sites underway for pivotal study of IMNN-001 ...

Short interest in Imunon Inc (NASDAQ:IMNN) increased during the last reporting period, rising from 997.88K to 1.20M. This put 8.29% of the company's publicly available shares short. Short interest ...

绿营支持者遭民众痛骂：连祖宗都不认，别用中国字！

Toon Van Gorp, MD, PhD, discussed findings from the MIRASOL trial and the potential of mirvetuximab to redefine treatment paradigms in ovarian cancer.

Imunon, Inc. is a clinical stage oncology drug company. It focuses on cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy and RNA-based therapies. The firm is also ...

In trading on Friday, shares of Ellington Financial Inc (Symbol: EFC) crossed below their 200 day moving average of $12.71, changing hands as low as $12.27 per share. Ellington Financial Inc ...

The COVID-19 pandemic reshaped how the world views vaccine development, disease preparedness and public health innovation. Nearly five years on from the global emergency declaration, it’s clear that ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

With the recent sign-off from the FDA on protocols for a pivotal Phase 3 trial of IMNN-001 in advanced ovarian cancer, Imunon is poised to bring its IL-12 DNA plasmid vector (encased in a nanoparticle ...